BrainStorm Cell Therapeutics News: Disease Study With NVIDIA

BrainStorm Therapeutics, a San Diego-based startup, is employing AI-powered computational drug discovery in conjunction with lab studies to speed up the development of treatments for these illnesses

NVIDIA BioNeMo Framework, a set of programming tools, libraries, and models for computational drug development, was utilized to generate BrainStorm Therapeutics'  cloud-based AI models

In order to find promising targets for possible medications and clinical biomarkers, BrainStorm Therapeutics employs AI algorithms to create gene maps of brain illnesses

BrainStorm Therapeutics is using organoids from Parkinson's sufferers to develop new treatments. The condition is caused by the death of neurones that create dopamine, a neurotransmitter that helps with movement and cognition

The BrainStorm team used single-cell sequencing data from brain organoids to refine BioNeMo Framework core models like the Geneformer model for gene expression analysis

BrainStorm’s patented technology allows it to replicate the biology of the human brain and model the potential effects of various treatments on a patient’s brain

By combining BrainStorm’s  AI-powered organoid technology with NVIDIA’s accelerated computing resources and the NVIDIA BioNeMo platform